Document is current
Any future updates will be listed below
-
Authors
Kim, Yuhree
Zhang, Fang
Su, Katherine
LaRochelle, Marc
Callahan, Matthew
Fisher, David
Wharam, J. Frank
Asgari, Maryam M. https://orcid.org/0000-0003-1582-3475
-
Funding
Funding for this research was provided by:
National Institutes of Health (K24 AR069760)
National Institutes of Health (R01CA222871)
- License Information
-
More Information
Article History
Received: 8 October 2019
Accepted: 17 June 2020
First Online: 24 June 2020
Compliance with Ethical Standards
: This study was approved by the Harvard Pilgrim Health Care Institutional Review Board.
: Dr. Fisher has a financial interest in Soltego, Inc., a company developing SIK inhibitors for topical skin darkening treatments that might be used for a broad set of human applications. Dr. Fisher’s interests were reviewed and are managed by Massachusetts General Hospital and Partners Healthcare in accordance with their conflict of interest policies.
Free to read: This content has been made available to all.
